Strand Life Sciences, a Reliance Industries subsidiary, has got a patent in India for its integrated platform for the early detection of cancer using cell-free DNA (cfDNA) analysis, it said.

The patent strengthens the company’s intellectual property portfolio in liquid biopsy and reinforces its strategy of developing integrated, AI-enabled molecular approaches for early cancer detection and precision oncology, the company said.

The patented platform brings together high-quality sequencing, “biologically informed methylation and fragmentomic feature extraction”, besides machine learning to enable cancer detection and tissue-of-origin prediction - from a blood sample.

“Widespread methylation pattern changes across the genome are a hallmark of cancer. A key innovation in the patent, among others, is obtaining these methylation patterns using genome sequencing with minimal loss or failure, thus enabling sensitive early cancer detection,” the company explained.

More than 1.5 million new cancer cases are estimated to occur annually, and several patients are still diagnosed at advanced stages, when treatment options are limited and outcomes are significantly poorer, a note from the company said.

“Current guideline-recommended screening covers only a small fraction of cancers and is not easy to scale. With decreasing costs of sequencing, the patented platform can potentially enable early detection at scale without expanding local infrastructure,” it added.

“Early detection is an increasingly relevant topic as cancer is becoming one of India’s greatest public health challenges,” said Ramesh Hariharan, CEO, Strand Life Sciences, adding that their efforts in developing AI-enabled liquid biopsy technologies was critical in making precision cancer screening more accurate, scalable, and accessible, he added.

()

Published on July 7, 2026